- Global Pharma News & Resources

UKRI-funded breakthrough research breathes hope into a new treatment for asthma

An international team of scientists, led by the University of Glasgow, has announced findings that could pave the way to a new treatment for asthma and chronic obstructive pulmonary disease (COPD).

The breakthrough findings, published in Science Translational Medicine, identify a new class of drugs that reverse the symptoms of asthma in animal models. The work was funded by the Medical Research Council (MRC) and the Biotechnology and Biological Sciences Research Council (BBSRC).

Researchers also found that the same drugs, when applied to lung samples obtained from human donors, showed effects similar to those seen in the animal models. Scientists believe that these combined findings offer new hope that these drugs could provide new medicines for human inflammatory lung disease.

The drugs used by the Glasgow team, work through a mechanism that is distinct from currently prescribed medicines for asthma and COPD. The findings describe a route to alternative treatments for patients suffering from severe forms of asthma and COPD, that are not controlled by current frontline treatments.

The new approach is centred on the activation of a protein that, up until now has been known to respond to fats contained in our diet. The protein, called free fatty acid receptor 4 (FFA4), is found in the gut and pancreas where it is activated by dietary fats including the fish oil omega 3. Once activated FFA4 is known to help control levels of glucose in our blood.

Surprisingly the Glasgow team found FFA4 is also present in human lung.

Professor Graeme Milligan, Gardiner Chair of Biochemistry at the University of Glasgow, added: “We were delighted to see the effectiveness of this class of drugs in relieving the symptoms caused not only by agents that result in asthma but also by pollutants and cigarette smoke.” 

The paper, ‘Pathophysiological regulation of lung function by the free fatty acid receptor FFA4’ is published in Science Translational Medicine. Read more on the University of Glasgow’s website.